You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Developing a novel adjuvant system for therapeutic vaccines against lung cancer
SBC: FasCure Therapeutics LLC Topic: 102DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A High Resolution Radiation Therapy Dosimetry system
SBC: DOSEIMAGING, LLC Topic: 399DESCRIPTION provided by applicant Modern radiation therapy treatment modalities such as intensity modulated radiation therapy are associated with complex dose distributions and sharp dose gradients Experimental dose validation using multidimensional high spatial resolution dosimeters is mandatory The product to be developed is a novel high resolution dosimetry system that combines reusabil ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
PEGYLATED PEPTIDES LIGANDS TARGETING RADIATION-INDUCIBLE RECEPTORS ON CANCER
SBC: Medical Guidance Systems LLC Topic: 102DESCRIPTION provided by applicant The proposed research is the study of new paradigms in both the treatment of cancer and cancer drug development This platform technology will markedly expand the number of cancer specific surface receptors and antigens that can be targeted for drug delivery using peptide ligands The general principle of this new technology is that cancer cells respond to ioni ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Temozolomide Perillyl Alcohol Conjugate as Treatment for Recurrent Malignant Brain tumors
SBC: NEONC TECHNOLOGIES INC Topic: BTDESCRIPTION provided by applicant Glioblastoma multiforme GBM the most common and malignant of all gliomas has a median survival time of months Standard of care chemotherapy using temozolomide TMZ is effective initially but the GBM inevitably recurs and these recurrent tumors are resistant to TMZ There are currently no effective treatment options for patients with TMZ resistant ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Carbon Fiber Off-Loading Orthosis
SBC: Orthotic & Prosthetic Design, Inc. Topic: 200DESCRIPTION provided by applicant This proposed project will further develop a CFC off loading AFO designed to offload plantar pressures and optimize patient function through maximizing plantarflexor power production During Phase I we will determine the effects of varying design characteristics of CFC off loading AFOs We will refine and create new FEA models and algorithms that predict the ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment
SBC: BIOVINC, LLC Topic: NIDCRDESCRIPTION provided by applicant Infectious bone disease is a major cause of morbidity and mortality worldwide Successful treatment often requires surgical intervention with longer term antibiotic therapy Bacterial biofilm pathogens are associated with most osseous infections and represent a major target of therapy The biofilm pathogens associated with chronic bone infections bind to and co ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Testing of Tetrandrine against Noise-Induce Hearing Loss
SBC: GATEWAY BIOTECHNOLOGY, INC. Topic: RDESCRIPTION provided by applicant Noise is the most common occupational and environmental hazard thus it is not surprising that noise induced hearing loss NIHL is the second most common form of sensorineural hearing deficit second only to age related hearing loss Although therapeutics that target the free radical pathway have shown promise for reducing NIHL there are no medications approv ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of an Osteoinductive Spinal Fusion Implant for Enhanced Fusion Rates
SBC: EVOKE MEDICAL LLC Topic: NIAMSDESCRIPTION provided by applicant The objective of this Phase I STTR research is to develop and test osteoinductive lumbar spinal fusion implant prototypes made using materials technology developments discovered by the PI at the University of Kansas In preliminary work lower impedance piezoelectric composite materials that generate power for direct current DC electrical stimulation applica ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
A method for accurate and sensitive detection of HIV drug-resistant minority variants
SBC: Medosome Biotec, LLC Topic: NIAIDDESCRIPTION provided by applicant Drug resistance to HIV is a major threat to achieving long term viral suppression in HIV individuals Up to of newly infected individuals acquire HIV with resistance to at least one of the major antiretroviral classes and incomplete viral suppression and virologic failure are often associated with drug resistance Therefore current DHHS guideline recomme ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
An epitope focused nanoparticle vaccine for MRSA and biodefense
SBC: VLP BIOTECH, INC. Topic: NIAIDDESCRIPTION provided by applicant Overall Staphylococcus aureus is a gram positive bacteria which possesses a multitude of virulence factors It is a frequent and severe pathogen in hospitals and of increasing concern in the community where it results in severe skin infections pneumonia bacterial endocarditis and sepsis A significant proportion of these infections are the result of methici ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health